TherapeuticsMD Second Quarter 2025 Earnings: EPS: US$0.047 (vs US$0.091 loss in 2Q 2024)

TherapeuticsMD (NASDAQ:TXMD) Second Quarter 2025 Results

Key Financial Results

• Net income: US$545.0k (up from US$1.05m loss in 2Q 2024).
• EPS: US$0.047 (up from US$0.091 loss in 2Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

TherapeuticsMD shares are up 8.3% from a week ago.

Risk Analysis

Be aware that TherapeuticsMD is showing 2 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.